Pharmacy Brief - December 2020
Welcome to the December edition of our Pharmacy Brief. This edition includes:
- GPhC annual report
- NHS Resolution annual report
- DHSC pushes back publication of new PNAs
- New terms of service requirements for distance selling pharmacies
- Premises enforcement by the GPhC
- What’s in store for 2021?
- It’s a deal
Whilst making predictions is always risky (the events of 2020 being an obvious example), I thought I would get my crystal ball out and see what 2021 might bring. You can watch me outline what I see in store for the Pharmacy sector here.
To read the brief in full, please click here.
For more information please contact Noel on +44 (0)20 7203 5395 or noel.wardle@crsblaw.com.
Our thinking
Melania Constable
Melania Constable and Georgina O'Sullivan write for P3 Pharmacy on the easing of Covid winding up restrictions
Regulations mean that a creditor can once again rely on an unpaid statutory demand to apply to the court for a winding-up petition.
Georgina O'Sullivan
Amelia Goodwin and Georgina O'Sullivan write for P3 Pharmacy on the key to managing performance
Day-to-day management is time consuming enough, so if you have a workforce with no apparent issues, performance may not be on your radar.
Tim Jenkins
Pharmacy Brief - September 2021
The September edition of our Pharmacy Brief
Noel Wardle writes for P3 Pharmacy on whether pharmacies have to provide medicines in compliance aids
Do pharmacies have to provide medicines in compliance aids, and can they can charge for them?
Lauren Kelly
Jennifer Berritt and Lauren Kelly write for P3 Pharmacy on The Lease Code and looking for better lease terms
The Lease Code published by The Royal Institution of Chartered Surveyors took effect on 1 September 2020.
Noel Wardle wrote for Chemist & Druggist on the implications of the new Health and Care Bill mean for community pharmacy
The government has now published its proposed overhaul of health and care in England.
Tim Jenkins
Charles Russell Speechlys advises Avicenna Group on duo of pharmacy group acquisitions
The acquisition takes Avicenna to a total of 135 pharmacy branches.
Pharmacy Brief - June 2021
The June edition of our Pharmacy Brief
Samuel Milne
Sam Milne writes for Pharmacy Business on the process of selling a pharmacy
Sam Milne outlines the process in making that all important decision to sell a pharmacy.
Noel Wardle quoted by Chemist and Druggist on how to make hub-and-spoke work for all independent pharmacies
Noel considers whether patients would be for or against their prescription being assembled at a hub, rather than a pharmacy.
Noel Wardle writes for Pharmacy Business on the balancing act of medicine supply
Do community pharmacies have to provide medicines in compliance aids, and can they charge for the service?
Rachel Warren
Property Patter: Navigating the complexities of Pharmacy Property
Pharmacy property is a specialist area which contains many traps for the unwary.
Georgina O'Sullivan
Amelia Goodwin and Georgina O'Sullivan write for Pharmacy Business on managing employee performance
Why contractors should prioritise performance management of employees as a regular feature of their business strategy.
Pharmacy Brief - March 2021
The March edition of our Pharmacy Brief
Natalie Deuchar
Natalie Deuchar and Leonora Owens write for Pharmacy Business on the considerations to take into account when pharmacists look to obtain a new unit
Pharmacists should be aware of the law when considering obtaining a new unit.
Noel Wardle quoted by Chemist and Druggist on the issues that need to be considered before pharmacies adopt a hub-and-spoke dispensing model
Under current legislation, the hub-and-spoke model can be carried out by pharmacies owned by the same legal entity.
Noel Wardle writes for Chemist and Druggist on how pharmacists can supply the COVID-19 vaccine lawfully
Pei-Li Kew writes for P3 Pharmacy on the differences between share and asset transactions when buying a pharmacy
Noel Wardle writes for Pharmacy Business on whether a notice to close a pharmacy can be withdrawn
Noel Wardle writes for Chemist & Druggist on the downsides of the new MUR legislation